OSUR - Sector: Healthcare***Industry: Medical Equipment & Supplies

[setravis]

Press Release Source: NASDAQ


Surgeon General, Vice Admiral Richard H. Carmona, M.D., Along With Five NASDAQ Biotechnology Companies Working on New AIDS Solutions to Ring NASDAQ's Opening Bell and to Host Press Briefing in Honor of World AIDS Day
Tuesday November 29, 12:56 pm ET


Press Conference to Follow Immediately After Opening Bell


(MARKET WIRE)--Nov 29, 2005 --
What:
The Nasdaq Stock Market, Inc. will host a special opening bell ceremony and press briefing in honor of World AIDS Day.

Who:

Surgeon General, Vice Admiral Richard H. Carmona, M.D. will preside over the opening bell. Joining the Surgeon General at the podium will be senior officials of NASDAQ Listed Companies, who are leading important product and research efforts largely focused on the AIDS virus.

--  Joshua Boger, Chairman, President and CEO, Vertex Pharmaceuticals
    Incorporated. (NasdaqNM:VRTX - News)
--  Dr. Nancy Chang, CEO of Tanox, Inc. (NasdaqNM:TNOX - News)
--  Paul Maddon, CEO of Progenics Pharmaceuticals, Inc (NasdaqNM:PGNX - News)
--  Douglas Michels, President and CEO of  OraSure Technologies, Inc.
    (NasdaqNM:OSUR - News)
--  Ronan O'Caoimh, Chairman & CEO Trinity Biotech plc (NasdaqNM:TRIB - News)
Where:

NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio & NASDAQ Press Conference Area.

When:

Thursday December 1st, 2005

--  Opening Bell ceremony will begin at 9:15 a.m. EST
--  Press Conference will begin at 10:00 a.m. EST
About the Press Conference:

Congress, in 1988, expressed its deep concern about the pandemic proportions of the Acquired Immunodeficiency Syndrome (AIDS). Noting that the World Health Organization has declared December 1, 1988 as World AIDS Day, Congress stressed the importance of observing that occasion yearly.

The following topics will be addressed by participating companies along with remarks by the Surgeon General, Vice Admiral Richard H. Carmona, M.D. at the NASDAQ Press Conference;

--  Advancement in treating the disease and the introduction of antiviral
    therapy;
--  The importance of testing for the disease in the fight against HIV in
    both in the U.S. and globally;
--  The role of Viral Entry Inhibitors as an emerging class of HIV/AIDS
    therapeutics; and,
--  The future of AIDS drugs and the side effects.
RSVP:

To RSVP to the Opening Bell and Press Conference please email and specify which event(s) you plan on attending:

Stephanie Lowenthal
[email protected]
Feed Information for the Opening Bell:

The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA-5 C-band/transponder 14. The downlink frequency is 3980 horizontal; audio: 6.2/6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice. Photos for the Press Briefing available upon request.

Opening Bell WebCam:

If you'd like to view the NASDAQ Opening Bell, simply click on this link http://www.nasdaq.com/reference/marketsite_about.stm and the following:

Viewers must have Windows Media Player to view the web cam
Scroll to the bottom of the page under the heading MarketSite Live Web cam
and click on Windows Media Player.
Conference Dial-In Number:

For those of you who can't attend, please use this dial-in number to participate in the conference. You will be able to listen and ask questions.

Dial In # 866.362.4831
International Dial In # 617.597.5347
Participant Passcode 87454635



Contact:
     Press Contacts:
     
     For more additional details, to book interviews, or for information about
     each participating company or the Surgeon General, please contact the
     appropriate person below:
     
     Surgeon General, Vice Admiral Richard H. Carmona, M.D.
     Jessica Badger
     Communications
     T: 202-690-6343
     Email Contact
     
     OraSure
     Erika Freed
     Zer0 to 5ive
     T: 212-699-3696
     Email: Email Contact
     
     Progenics
     Victoria Hofstad
     Citigate Sard Verbinnen
     T: 212-687-8080
     Email: Email Contact
     
     Edie De Vine
     Progenics Pharmaceuticals, Inc.
     T: 914-789-2818
     Email: Email Contact
     
     Tanox
     Steve Sievert
     Tanox, Inc.
     T: 713-578-4211
     Email: Email Contact
     
     Trinity Biotech
     Jonathan Neilan
     K Capital Source
     Capital Market
     Communications and Advisory
     T: 353-1-631-5520
     Email: Email Contact
     
     Vertex
     Zachry A. Barber
     Vertex Pharmaceuticals Incorporated
     T: 617-444-6470
     Email: Email Contact
     
     NASDAQ:
     Silvia Davi
     T: 646-441-5014
     Email: Email Contact
     
     Stephanie Lowenthal
     T: 646-441-5220
     Email: Email Contact
     


--------------------------------------------------------------------------------
Source: NASDAQ

[eliteG]

O'sure like this play has a chance of going down after the mighty setravis picked it! 

really great play hawkeye  well done.  Born to pick stocks 

[setravis]

O'sure like this play has a chance of going down after the mighty setravis picked it!

really great play hawkeye well done. Born to pick stocks

Thank's Wizard, "The Elite One !" We were born to do something, I guess we here @ 3SOF just like to dabble in stocks.  Keep up your outstanding "G"-MAN 
But sure looks like old Lucas Scott ans his GTE put one on all of us. 

[eliteG]

if it was only a shorting contest..    yep GTE turned out to be quite a pick

[setravis]

OSUR...Let's rock and roll today....

Press Release Source: OraSure Technologies, Inc.


OraSure Launches OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test in Mexico
Wednesday November 30, 6:00 am ET 
Event to Be Held at CENSIDA'S Ninth HIV/AIDS Conference on November 30th at 7:00 PM CST


BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 30, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR - News), the market leader in oral fluid diagnostics, announced today the launch of its OraQuick® ADVANCE(TM) Rapid HIV-1/2 Antibody test in Mexico. OraQuick® ADVANCE(TM) is the only FDA approved and CLIA waived oral fluid rapid HIV-1/2 test currently available in the United States, and will be the only oral fluid rapid HIV test available in Mexico.


The OraQuick® ADVANCE(TM) test will be sold by the Company's exclusive distributor in Mexico, Spite S.A. de C.V., to the National Health Sector, National Council for HIV/AIDS, State HIV programs, non-governmental organizations, hospitals, clinics, physicians and other members of the professional healthcare community in Mexico.

"Mexico is committed to the prevention of HIV/AIDS through increased HIV testing and education," said Dr. Jorge Saavedra, Director General of the Mexico Center for the Prevention and Control of HIV/AIDS (CENSIDA). "Rapid tests such as the OraQuick® ADVANCE(TM) test will be an integral part of Mexico's HIV prevention campaign, enabling us to provide the most versatile and comprehensive rapid HIV tests available to our HIV testing agencies across the country."

"Following the great success of the OraQuick® ADVANCE(TM) test in the U.S. we are pleased to be launching the product into a market as important as Mexico," said Douglas A. Michels, President and CEO of OraSure Technologies. "This launch represents a significant step in an international strategy to extend our distribution network south of the United States into Mexico and ultimately into Central and South America and the Caribbean. We look forward to working with the Mexico Ministry of Health and other national, state and local agencies to expand HIV testing in Mexico and help fight HIV/AIDS in that country."

Mexico has a current population of approximately 106 million people. According to the Joint United Nations Program on HIV/AIDS (UNAIDS), Mexico has 160,000 adults and children living with HIV/AIDS. AIDS caused around 5,000 deaths in 2003.

OraQuick® ADVANCE(TM) Rapid HIV-1/2 Antibody Test, manufactured by OraSure Technologies, is the first and only FDA approved and CLIA waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood or plasma specimens. OraSure received regulatory approval for its OraQuick® ADVANCE(TM) test from the Mexico Ministry of Health in September 2005.

A press conference to announce the launch of OraQuick® ADVANCE(TM) in Mexico will be held today by Spite and OraSure Technologies at 7:00 PM CST (19:00 hrs) at the 9th Mexican National HIV/AIDS Conference taking place at the Hotel Mision San Felipe in Oaxaca, Mexico. Representatives of CENSIDA and the Government of Oaxaca will also be in attendance.

OraSure will also be exhibiting at the 9th Mexican National HIV/Aids Conference, which will take place December 1 - 3, 2005 at the Hotel Mision San Felipe Oaxaca. Av. Jalisco No.15, Zona Residencial San Felipe del Agua Col. San Felipe del Agua, Ciudad de Oaxaca C.P. 68020 in booth # 11.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of HIV. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to http://www.orasure.com.

About Spite S.A. de C.V.

Spite, S.A. de C.V. is a Mexican company created in 1991, dedicated to the distribution of general use health items, focusing mainly to the Health Sector having personnel with over 40 years of experience in the pharmaceutical industry. For more information on the Company, please go to www.spitefarmacos.com

Important Information

This press release contains certain forward-looking statements, including with respect to revenues, product shipments and commercialization activities. Actual results could be significantly different. Factors that could affect results include the ability to market products; impact of competitors, competing products and technology changes; ability to develop, commercialize and market new products; market acceptance of oral fluid testing products and other new products or technology; ability to fund research and development and other projects and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical product components; availability of related products produced by third parties; ability to obtain, and timing of obtaining, necessary regulatory approvals; ability to comply with applicable regulatory requirements; history of losses and ability to achieve sustained profitability; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally; loss or impairment of sources of capital; ability to meet financial covenants in agreements with financial institutions; ability to retain qualified personnel; exposure to product liability, patent infringement, and other types of litigation; changes in international, federal or state laws and regulations; changes in relationships with strategic partners and reliance on strategic partners for the performance of critical activities under collaborative arrangements; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; ability to complete consolidation or restructuring activities; ability to identify, complete and realize the full benefits of potential acquisitions; and general political, business and economic conditions. These and other factors are discussed more fully in the Securities and Exchange Commission ("SEC") filings of OraSure Technologies, including its registration statements, its Annual Report on Form 10-K for the year ended December 31, 2004, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Although forward-looking statements help to provide complete information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.



Contact:
OraSure Technologies, Inc.
Investor Contact:
Ronald H. Spair, 610-882-1820
[email protected]
www.orasure.com
    or
Media Contacts:
Jennifer Moritz, 917-748-4006
[email protected]
    or
Ron Ticho, 610-882-1820
[email protected]

--------------------------------------------------------------------------------
Source: OraSure Technologies, Inc.

[setravis]

Press Release Source: OraSure Technologies, Inc.


OraSure Technologies Opens NASDAQ and Donates OraQuick(R) ADVANCE(TM) Tests in Recognition of World AIDS Day
Thursday December 1, 8:27 am ET 
OraSure Also Receives Red Ribbon Leadership Award


BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 1, 2005--OraSure Technologies, Inc. (NASDAQ:OSUR - News), the market leader in oral fluid diagnostics, today announced it will participate in opening the NASDAQ Stock Market and donate up to 100,000 OraQuick® ADVANCE(TM) Rapid HIV-1/2 Antibody Test kits to several African countries and to India in recognition of World AIDS Day, a global effort that is commemorated annually on December 1st. OraSure President and CEO, Douglas A. Michels will announce this significant initiative at the NASDAQ Market Open ceremony this morning in New York City.


Following the NASDAQ open, Mr. Michels will participate in a special NASDAQ-sponsored panel discussion and press conference on global HIV/AIDS prevention and treatment, featuring United States Surgeon General, Vice Admiral Richard H. Carmona, M.D.

World AIDS Day is an international day of observance to honor those who have died from AIDS, as well as increase awareness of the disease in hopes of fighting the further spread of HIV. The United Nations estimates that there are now more than 40 million people living with HIV/AIDS around the world, and of people living with HIV, only one in 10 has been tested and knows that he or she is infected.

OraSure Technologies also announced that it has been awarded a "Red Ribbon Leadership Award" by the National HIV/AIDS Partnership (NHAP). The Red Ribbon Leadership Awards, in their inaugural year, recognize individuals or entities that demonstrate outstanding leadership in promoting behaviors, directing activities, and exemplifying qualities that inspire others to take actions to stop HIV transmission. Award recipients were selected by a panel representing a range of public and private sectors. The award will be announced today at a special ceremony at the United Nations world headquarters in New York City by the membership of the NHAP.

In addition, OraSure announced yesterday the launch of its OraQuick® ADVANCE(TM) Rapid HIV-1/2 Antibody test in Mexico, currently the only oral fluid rapid HIV test available in Mexico. The OraQuick® ADVANCE(TM) test will be sold by the Company's exclusive distributor in Mexico, Spite S.A. de C.V., to the National Social Medicine Services, National Council for HIV/AIDS, State HIV programs, non-governmental organizations, hospitals, clinics, physicians and other members of the professional healthcare community in Mexico.

"This year's World AIDS Day is especially exciting for OraSure, as we've made significant strides in extending our global reach in the fight against HIV - first, by launching OraQuick® ADVANCE(TM) in Mexico and, second, by donating a significant number of test kits to Africa and India - countries that have been hard-hit by the HIV/AIDS epidemic," said Douglas A. Michels, President and CEO of OraSure Technologies. "Furthermore, OraSure is honored to once again open the NASDAQ Stock Market and to receive a Red Ribbon Leadership Award on such a meaningful day."

At the local level, OraSure is supporting World AIDS Day testing events in major cities across the United States, including Chicago and New York City, where partner sites are launching rapid oral fluid HIV testing initiatives with OraQuick® ADVANCE(TM).

The OraQuick® ADVANCE(TM) Rapid HIV-1/2 Antibody Test, manufactured and sold by OraSure Technologies, is the first and only U.S. Food and Drug Administration ("FDA") approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood and plasma specimens.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of HIV. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to http://www.orasure.com.



Contact:
OraSure Technologies, Inc.
Investor Contact:
Ronald H. Spair, 610-882-1820
[email protected]
www.orasure.com
    or
Media Contacts:
Erika Freed, 212-699-3696 or 917-359-7974
[email protected]
    or
Ron Ticho, 610-882-1820
[email protected]

--------------------------------------------------------------------------------
Source: OraSure Technologies, Inc.

[setravis]

 

http://www.rallymonkey.com/video/kenindex.swf

[setravis]

From a pure technical view at the close, bullish engulfing candlestick pattern.This usually means a few more bullish sessions.
As I had hoped, OSUR formed it's Cup with Handle and then broke out on good volume.
After Hours: $14.34

Support @ $13.47...12.93...12.44
MACD is Bullish.........
Stochastic is Bullish.....

Volume: 1,340,356........
Avg Vol (3m): 601,222

Technicals
Last Price Quote is:
13.86%above 13-day EMA
27.48%above 50-day EMA
RS Rating: 97 

Fundamentals
Key Data:
Market Cap (M): $555.86 
P/E Ratio: 85.88 
PEG Ratio: 2.29667 
Next Earnings: 02/09/2006
Last Analyst Rating: Hold

[peterwangos]

Hi:

There is a gap between 12.50 -- 12.90. Should it be filled soon?

Peter

[setravis]

OSUR - ORASURE TECH INC (NASDAQ)
Date        Open   High     Low     Last      Change    Volume       % Change 
12/02/05  13.31   13.94  13.17  13.94   +0.61       1340300      +4.58%


Composite Indicator 
   Trend Spotter TM Buy 
 
Short Term Indicators 
   7 Day Average Directional Indicator Buy 
   10 - 8 Day Moving Average Hilo Channel Buy 
   20 Day Moving Average vs Price Buy 
   20 - 50 Day MACD Oscillator Buy 
   20 Day Bollinger Bands Buy 
 
Short Term Indicators Average:   100% - Buy
20-Day Average Volume - 1179945
 
Medium Term Indicators 
   40 Day Commodity Channel Index Buy 
   50 Day Moving Average vs Price Buy 
   20 - 100 Day MACD Oscillator Buy 
   50 Day Parabolic Time/Price Buy 
 
Medium Term Indicators Average:   100% - Buy
50-Day Average Volume - 719724
 
Long Term Indicators 
   60 Day Commodity Channel Index Buy 
   100 Day Moving Average vs Price Buy 
   50 - 100 Day MACD Oscillator Buy 
 
Long Term Indicators Average:   100% - Buy
100-Day Average Volume - 638868
 
Overall Average:   100% - Buy
 
Price  Support  Pivot Point  Resistance 

13.94  12.91  13.68  14.45 

[setravis]

Profile Get Profile for: 
 

Onstream Media Corp.
1291 SW 29 Avenue
Pompano Beach, FL 33069
Phone: 954-917-6655
Fax: 954-917-6660
Web Site: http://www.onstreammedia.com

DETAILS   
Index Membership: N/A
Sector: Technology
Industry: Business Software & Services
Full Time Employees: 61


BUSINESS SUMMARY   
Onstream Media Corporation operates as a broadband media company that provides video and media communication, Webcasting, and digital asset management services. Its Webcasting services include an array of corporate-oriented, Web-based media services to the corporate market, including live audio and video Webcasting, and on-demand audio and video streaming for various businesses, government, or educational entities. The company also produces Internet-based multimedia streaming videos. The company's digital asset management (DAM) services consist of a set of coordinated technologies and processes that enable the storage, retrieval, and reuse of the digital files, such as photos, videos, audio files, engineering specs, architectural plans, Web pages, and other pieces of business collateral. In addition, DAM services provide connectivity within the entertainment and advertising industries through its private network; systems integration and engineering services; application-specific technical advice; audio equipment; video compression and transport equipment; teleconferencing equipment; and other products to facilitate its broadcast and production applications. Onstream Media offers its products in the United States through internal sales force and channel partners. The company was formed under the laws of Florida in 1993. It was formerly known as Visual Data Corporation and changed its name to Onstream Media Corporation in January 2005. Onstream Media is headquartered in Pompano Beach, Florida.

[setravis]

Low float...
Float (mil) 8.70, Shares Outstanding (mil) 11.20

Business Overview
BRIEF: Onstream Media Corp. is a multimedia content producer, marketer and distibutor of advertising products and consumer-based portfolio libraries for use on the Internet, and, eventually, Interactive Television. For the 9 months ended 6/30/05, revenues rose 11% to $6.2M.

Support @ 0.94...0.90...0.86
Resistance @ $1.01...1.03...1.07

MACD is Bullish..........MACD fell to centerline and bounced .
Stochastic is neutral

Recent CandleStick Analysis
Very Bullish
Dec-29-2005 Bullish Engulfing 
Dec-28-2005 Homing Pigeon 
Dec-27-2005 Inverted Hammer 

[peterwangos]

Do not know whether anyone still has any position. But post here anyway.

From Yahoo board -- http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=7076819&tid=epto&sid=7076819&mid=37295&thr=37215&cur=37215&dir=d .

 
Final Score: OraQuick Advance Wins
by: dreamer1976md
Long-Term Sentiment: Strong Buy  03/01/06 11:36 am
Msg: 37295 of 37307

On behalf of those that believe in media fairness and responsibility and especially on behalf of the unfortunate individuals that may have taken their uniformed reports seriously, I would love to see what Bluehairdriver stated on his last paragraph of Post 37292 happen.

Here is the final score as I see it.

Team Humanity & OraQuick Advance is the winner, scoring a 99.6% Specificity Rate.

Team S.F. Chronicle & Talk Show Host gets disqualified for False Positive Reporting.

Those unfortunate souls that perhaps missed early detection of infection because they did not go for testing after the uniformed reports surfaced of course stand to lose the most. Also hurt were those investors that were scared into selling their precious OraSure shares.

On the positive side, those wise readers of this Yahoo! OraSure Board benefited handsomely if they bought more shares of their beloved OraSure when its value plunged as a result of the uninformed reports. I am proud to include Dreamer as one of these.

Goldman Sachs and Merrill Lynch apparently did the same. Although I made a humorous reference to this in Post 36821, I honestly believe that in all probability they did read this Board. Indeed, for the reasons I previously mentioned, it would be irresponsible for anyone to make such large purchases of our beloved OraSure without at least skimming through the precious information and insight on this Board.

Anyone who read Post 33558 by the distinguished Dr. ARCruz should have realized that in all likelihood, there was nothing wrong with OraQuick Advance. Student researcher Wsucbaker then hammered this home with Post after Post of incredibly informative and insightful first-hand analysis of the astounding actual performance of OraQuick Advance.

And long before the CDC Report by Dr. Branson and about a week even before CEO Doug Michels? initial Report, a certain Dreamer on this Board calculated the overall Specificity of OraQuick Advance, including the False Positives, to be an astounding 99.2% (Post 31913, December 11, 2005).

Of course, an anguished Dreamer tried to share his analysis of the False Positive situation with passionate letters to both the S.F. Chronicle (Post 32484) and to the said TV Host (Post 32370).

Now a word about Conspiracy Theory (a favorite film of this movie buff). It抯 my nature to look at everything from the positive side, so at first I dismissed entirely any possibility of conspiracy, despite reading the many Posts on this Board proposing this. Even though it makes me ill to think someone would stoop so low as to deliberately harm the reputation a life-saving product for the sake of profit, now I have my doubts. At about the same time the False Positive media reports surfaced, certain malicious and idiotic bashers appeared on this Board, some openly citing that a certain notorious hedge fund manager of ill-repute had recommended shorting our beloved OraSure stock. You decide.

To all OraSure believers, I think our Dream remains very bright. :-)

Sincerely,
Dreamer1976, M.D.



Posted as a reply to: Msg 37245 by dreamer1976md   
Message Thread [ Hide ] Profanity filter is Off [ Turn On ] 
Subject Author   Recs   Date/Time (ET)
[ Go up one level ]
   OraSure Intercept: The Future Is Oral  dreamer1976md    5    02/21/06 11:18 am
        Re: OraSure Intercept: The Future Is Ora  wishock60         02/21/06 01:42 pm
           OraSure Board Legal Team: A New Era  dreamer1976md         02/22/06 09:39 pm
              OraQuick: CDC Agrees With OraSure  dreamer1976md    1    02/23/06 01:53 pm
                 Re: OraQuick: CDC Agrees With OraSure  pesotrader         02/23/06 04:17 pm
                    Re: OraQuick: CDC Agrees With OraSure  chitownfatboy         02/23/06 07:48 pm
=>                Final Score: OraQuick Advance Wins  dreamer1976md    2    03/01/06 11:36 am
                    Re: Final Score: OraQuick Advance Wins  girardgriswold         03/01/06 04:41 pm
< Previous  |  Next > 

      < Previous | Next >  [ First | Last | Msg List ] Msg #:   Reply



   
All    Subject    Message Text    Authors   
   ADVERTISEMENT


OSUR Snapshot 
 
OSUR  9.73  +0.21  +2.21% 

Delayed data
providers - disclaimer

Symbol Lookup


--------------------------------------------------------------------------------
Chart, Financials, Historical Prices, Industry, Insider, Messages, News, Profile, Reports, Research, SEC Filings, more... 
Get Streaming Real-Time Quotes

with Yahoo! Finance




Reminder: This board is not connected with the company. These messages are only the opinion of the poster, are no substitute for your own research, and should not be relied upon for trading or any other purpose. Never assume that you are anonymous and cannot be identified by your posts. Please read our Terms of Service. For more information regarding investments and the Internet, please visit the SEC Web site.




--------------------------------------------------------------------------------

Copyright 2006 © Yahoo! Inc.  Privacy Policy | Terms of Service | Send Feedback | Help

[tokyopua]

Up 20% today on huge volume, CDC news calling for more AIDS testing.  Long upper shadow, but the volume makes me think it might be worth getting in here.  Anyone else watching this?

--------------------------------------------------

OraSure Technologies Applauds CDC`s Call for Routine HIV Testing; Revised HIV Testing Recommendations Advocate HIV Screening as Routine Part of Medical Care

September 21, 2006 14:39:11 (ET)


BETHLEHEM, Pa., Sep 21, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (OSUR, Trade), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, today issued a statement in support of "The Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health Care Settings," issued today by the Centers for Disease Control and Prevention ("CDC"). These recommendations, which advocate routine HIV screening of patients as a normal part of medical care, were published in the CDC's Morbidity and Mortality Weekly Report (MMWR), September 22, 2006/55 (RR14); 1-17.

According to the CDC, the objectives of the revised recommendations are to normalize HIV screening as a routine part of medical care, including for pregnant women, in health-care settings; foster earlier detection of HIV infection; identify and counsel persons with unrecognized HIV infection and link them to clinical and prevention services; and further reduce perinatal transmission of HIV in the United States. The recommendations are intended for all health-care providers in clinical settings, including those working in hospital emergency departments, urgent care clinics, inpatient services, substance abuse treatment clinics, public health clinics, community clinics, correctional health-care facilities and primary care settings. The full guidelines can be found at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm

"We believe the implementation of routine testing in health-care settings is an important step toward stopping the spread of HIV in America. We applaud the CDC for issuing this clear call to action, which will reduce barriers in both the public and private sector to HIV testing as a regular part of medical care," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "We are confident that as a result of the revised recommendations, more individuals will get tested and learn their HIV status, and we believe our OraQuick ADVANCE(R) test can serve an important role. We look forward to working with the CDC and health care providers as they advance this initiative."

The recommendations call for routine HIV testing of all patients aged 13 to 64. In contrast, the prior CDC guidelines recommended routine testing only for high-risk persons and for those in acute-care settings where HIV prevalence exceeded one percent. The new recommendations emphasize that testing be provided on a voluntary basis with the patient's knowledge, unless the patient elects to "opt out" of the testing. It is further recommended that HIV testing be covered by a general medical care consent obtained from the patient and that pre-test counseling and a separate written consent for HIV testing no longer be required. The recommendations also contain measures intended to improve diagnosis of pregnant women and further reduce mother-to-child HIV transmission.

The development of the recommendations involved extensive input from representatives of community-based organizations, individuals living with HIV/AIDS, health departments and academia, as well as representatives from professional organizations, state and federal agencies, and other stakeholders.

OraQuick ADVANCE(R) is the first and only U.S. Food and Drug Administration approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood or plasma specimens. The CDC and the Substance Abuse and Mental Health Services Administration (SAMHSA) have effectively deployed over one million OraQuick(R) tests in various public health, drug treatment and outreach settings throughout the country. OraQuick(R) is also used by hospitals, state departments of health, clinics, community-based organizations, and college/university health centers throughout the country.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV. In addition, the Company supplies oral fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

[tokyopua]

Monster volume today (scroll to the right if you cant see it on the chart below).

I am in tomorrow around the open and may add to my position if there is any pullback to the 50sma at 7.63, though I doubt that.  Looks like a cup is forming on the chart today and so a move above 10.16 should really move this stock, IMO.

http://finance.yahoo.com/q/bc?s=OSUR&t=1d